Creabilis rounds up $30M

CompanyAmount/RoundLead InvestorsDescription


Creabilis Therapeutics
Italy
$30.6M
First
Sofinnova Partners

The money is earmarked for three mid-stage studies of CT327 for psoriasis and dermatitis and CT200, which is being developed for Behcet's Disease.

IRX Therapeutics
New York
$25M
First
Existing investors

The new money will be used to further develop IRX's cancer and viral disease product platform, including IRX-2 (citoplurikin), its lead candidate for cancer treatment.

Inimex Pharmaceuticals
Canada
$22M
Second
Morningside Venture Investments

The company is launching the first clinical trials of an Innate Defense Regulator (IDR) drug in patients and assessing IDR drugs in a range of disease models.

Creabilis rounds up $30M

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.